PBAC's latest decision on Betaxolol, bimatoprost, bimatoprost + timolol, brimonidine, brimonidine + timolol, brinzolamide, brinzolamide + timolol, dorzolamide, dorzolamide + timolol, latanoprost, latanoprost + timolol, pilocarpine, timolol, travoprost, timolol + travoprost: Recommended with restriction (2015). Considered for Elevated intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension, including those with inadequately controlled monotherapy requiring combination therapy.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2015
Submissions
1
2015 → 2015
Eligible population
Authorised optometrists prescribing anti-glaucoma medicines for patients with elevated intra-ocular pressure, open-angle glaucoma, or ocular hypertension in accordance with Optometry Board of Australia guidelines.
Therapy area
Ophthalmology
Line of therapy
Not applicable
Evidence base
Other
Economic model
not-modelled
ICER note
not-modelled — Minor administrative submission with no economic evaluation